Praxis speeds up R&D plans for seizure therapy after FDA feedback
Praxis Precision Medicines (PRAX) on Tuesday announced an accelerated timeline in the development of its anti-seizure therapy, relutrigine, following positive feedback from the U.S. FDA. The Boston, Massachusetts-based biotech said that during a recent...
Seeking Alpha